- Home
- RGT vs SERA Comparison
RGT vs SERA Comparison
Compare RGT & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGT
- SERA
- Stock Information
- Founded
- RGT 1986
- SERA 2008
- Country
- RGT United States
- SERA United States
- Employees
- RGT N/A
- SERA N/A
- Industry
- RGT Trusts Except Educational Religious and Charitable
- SERA Precision Instruments
- Sector
- RGT Finance
- SERA Health Care
- Exchange
- RGT Nasdaq
- SERA Nasdaq
- Market Cap
- RGT 83.4M
- SERA 90.6M
- IPO Year
- RGT N/A
- SERA 2021
- Fundamental
- Price
- RGT $13.02
- SERA $3.25
- Analyst Decision
- RGT
- SERA
- Analyst Count
- RGT 0
- SERA 0
- Target Price
- RGT N/A
- SERA N/A
- AVG Volume (30 Days)
- RGT 22.4K
- SERA 64.5K
- Earning Date
- RGT 01-01-0001
- SERA 11-05-2025
- Dividend Yield
- RGT 1.43%
- SERA N/A
- EPS Growth
- RGT N/A
- SERA N/A
- EPS
- RGT 0.92
- SERA N/A
- Revenue
- RGT N/A
- SERA $108,000.00
- Revenue This Year
- RGT N/A
- SERA $217.92
- Revenue Next Year
- RGT N/A
- SERA $479.25
- P/E Ratio
- RGT $11.42
- SERA N/A
- Revenue Growth
- RGT N/A
- SERA 0.94
- 52 Week Low
- RGT $7.84
- SERA $1.37
- 52 Week High
- RGT $11.08
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- RGT 58.98
- SERA 58.22
- Support Level
- RGT $12.55
- SERA $2.87
- Resistance Level
- RGT $13.05
- SERA $3.12
- Average True Range (ATR)
- RGT 0.21
- SERA 0.23
- MACD
- RGT -0.02
- SERA -0.02
- Stochastic Oscillator
- RGT 64.86
- SERA 63.77
About RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.